ArticleClinical journal of gastroenterology2026
Muir-Torre syndrome in a patient with advanced duodenal carcinoma.
Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Muir-Torre syndrome (MTS) is a rare autosomal dominant disorder characterized by sebaceous neoplasms and visceral malignancies and is regarded as a phenotypic variant of Lynch syndrome. Although colorectal and genitourinary cancers are the most common visceral malignancies in MTS, duodenal cancer is extremely rare. We report a case of advanced duodenal cancer associated with MTS treated with multidisciplinary therapy. A 62-year-old man with a history of multiple colorectal cancers and sebaceous carcinomas presented with vomiting and epigastric pain. Upper gastrointestinal endoscopy revealed a circumferential tumor with stenosis in the fourth portion of the duodenum, and a biopsy showed moderately differentiated adenocarcinoma. Computed tomography suggested peritoneal dissemination, and the tumor was considered unresectable. Systemic chemotherapy with 5-fluorouracil and oxaliplatin resulted in tumor regression and disappearance of the suspected dissemination. Conversion surgery with partial duodenectomy and lymph node dissection was subsequently performed, achieving R0 resection. Genetic testing revealed microsatellite instability-high status and a pathogenic MSH2 mutation, confirming MTS. Although postoperative lymph node recurrence occurred, the disease has been controlled with immunotherapy and radiotherapy, and the patient remains alive two years after surgery. This case highlights the potential role of multidisciplinary treatment and the importance of recognizing MTS and implementing appropriate surveillance.
Indexed as
Identifiers
42832013What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.